Opioid abuse remains a significant public health problem; together with the greater availability of marijuana in some regions there is an increasing likelihood that opioids and marijuana will be used together. Polydrug abuse is associated with increased toxicity and poorer treatment outcome; thus, a better understanding of the consequences of repeated coadministration of these drugs will facilitate the development of better prevention and treatment strategies. This study examined the effects of daily treatment with the cannabinoid receptor agonist delta-9-tetrahydrocannabinol (Δ 9 -THC) and its discontinuation on self-administration of heroin in rhesus monkeys (n = 4) lever-pressing under a fixed-ratio 30 schedule. Heroin self-administration (0.32-32 μg/kg/infusion, intravenously) generated an inverted U-shaped dose-effect curve. Administered acutely, Δ 9 -THC (0.01-0.32 mg/kg, subcutaneously) dose dependently decreased responding for heroin and flattened the self-administration dose-effect curve. Daily treatment with Δ 9 -THC (0.01-0.1 mg/kg/12 h, subcutaneously) either had no effect on or decreased responding for heroin. In addition, daily treatment did not significantly impact extinction of heroin self-administration or resumption of responding for heroin after extinction. Discontinuation of daily Δ 9 -THC treatment did not systematically impact rates of heroin self-administration. These data suggest that repeated administration of a cannabinoid receptor agonist likely does not increase, and possibly decreases, the positive reinforcing effects of a mu opioid receptor agonist.
Introduction
Opioid abuse remains a significant public health problem (Zacny et al., 2003; Compton and Volkow, 2006; Manchikanti et al., 2012) . Heroin abuse has increased over the past decade [Substance Abuse and Mental Health Services Administration (SAMHSA), 2013] and abuse of prescription drugs, including opioids, is currently the second largest illicit drug problem in the USA behind the use of marijuana [Office of National Drug Control Policy (ONDCP), 2011]. The problem of opioid abuse is underscored by recent dramatic increases in opioid overdoses and deaths (Paulozzi, 2012; Calcaterra et al., 2013) . In addition to being abused alone, recent data indicate that opioids are increasingly used in combination with other drugs, with a large percentage of adolescent users reporting coadministration of prescription opioids with marijuana or alcohol (e.g. McCabe et al., 2012) . Polydrug abuse represents a particularly significant public health problem as it is associated with increased risk of toxicity and other adverse health consequences (e.g. Cone et al., 2004) as well as poorer treatment outcome (e.g. Williamson et al., 2006) . Given recent changes in the legal status of marijuana in some states in the USA, favoring decriminalization and legalization, and increasing trends in opioid abuse, coadministration of marijuana and other drugs such as opioids is likely to continue and possibly increase. A better understanding of the consequences of repeated coadministration of drugs will ultimately aid in the development of more effective prevention and treatment strategies for abuse.
Cannabinoid and opioid systems interact at multiple cellular and neurochemical levels (e.g. Vigano et al., 2005; Bushlin et al., 2010; Scavone et al., 2013) , notably impinging upon activity of neurotransmitters such as dopamine (e.g. Tanda and Goldberg, 2003) that are thought to underlie the abuse-related effects of many drugs. Neurochemical interactions between cannabinoid and opioid systems suggest that coadministration of cannabinoids and opioids might alter their abuse-related (e.g. positive reinforcing) effects. Recent studies in rhesus monkeys indicate that acute treatment with a cannabinoid receptor agonist [delta-9-tetrahydrocannabinol (Δ 9 -THC), 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol (CP 55940), or (R)-(1)- [2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo [1,2,3-de] -1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate (WIN 55, 212) ] does not enhance, and in some cases attenuates, the discriminative stimulus effects of opioids (Li et al., 2008; Maguire et al., 2013a) as well as self-administration of heroin (Li et al., 2012; Maguire et al., 2013a) , suggesting that the combination of a cannabinoid and an opioid might not have increased abuse potential, compared with either drug alone. However, interactions between the behavioral effects of opioids and cannabinoids appear to be influenced by an individual's history (e.g. repeated drug exposure). For example, although Δ 9 -THC attenuates the discriminative stimulus effects of morphine in nondependent rhesus monkeys, it has no effect on the discriminative stimulus effects of morphine in morphinetreated (i.e. opioid-dependent) monkeys (Li et al., 2008) . In humans, the opioid receptor antagonist naltrexone increases (Haney et al., 2003; Cooper and Haney, 2010) , decreases (Haney, 2007) , or has no effect on (Greenwald and Stitzer, 2000; Wachtel and de Wit, 2000) the subjective effects of Δ 9 -THC depending on the subject's history of marijuana use.
Drug abuse involves repeated administration of drugs, which can result in long-lasting neurobiological changes that might promote abuse (e.g. Luscher and Malenka, 2011) . Although previous work (e.g. Li et al., 2012; Maguire et al., 2013a) examining the acute effects of Δ 9 -THC and other cannabinoid receptor agonists on heroin self-administration are informative, studies examining the effects of repeated administration of drug combinations are required to fully characterize drug-drug interactions and to understand factors contributing to polydrug abuse. The goal of the current study was to determine whether repeated, daily treatment with a cannabinoid receptor agonist impacts the reinforcing effects of a mu opioid receptor agonist. Specifically, this study examined the effects of daily administration of Δ 9 -THC on various aspects of heroin self-administration in rhesus monkeys, including the following: (a) maintenance of heroin self-administration; (b) persistence of responding in the absence of heroin (extinction); (c) resumption of heroin self-administration following a period of extinction; and (d) possible changes in heroin self-administration that occur upon discontinuation of daily Δ 9 -THC treatment.
Materials and methods

Subjects
Four adult rhesus monkeys (Macaca mulatta), two male and two female, served as subjects; each had experience with heroin self-administration and had received acute injections of cannabinoid receptor agonists as well as other drugs (e.g. Li et al., 2012; Maguire et al., 2013a Maguire et al., , 2013b but did not receive any drug other than selfadministered heroin for at least 3 months prior to the current experiment. Age-appropriate and sex-appropriate body weight (range: 6.5-11.5 kg) was maintained via postsession feeding ( by a 20 G Huber-point needle (Access Technologies). The opposing end of the extension set was connected to a 30 ml syringe that was mounted in a syringe driver (Med Associates Inc.) located outside the chamber.
Surgery
Single-lumen silicone catheters (model SIL-C50; Instech Solomon, San Antonio, Texas, USA) were implanted and maintained according to procedures described previously (Maguire et al., 2013a) . Briefly, monkeys were initially sedated with 10 mg/kg of ketamine (subcutaneously) followed by the maintenance of anesthesia with isoflurane. The catheter was placed in either the jugular or femoral vein then tunneled subcutaneously to the midscapular region where it was attached to the subcutaneous access port.
Heroin self-administration
Sessions were conducted once daily, 7 days per week. Each 100 min session comprised four 25 min cycles. Each cycle began with a 5 min timeout period, during which all lights were extinguished and responding had no programmed consequence, followed by a 20 min response period. A priming infusion of the unit dose of heroin that was available for self-administration in each cycle was delivered immediately prior to the beginning of the response period. During the response period, a green light located above the active lever (left lever for monkeys NA and PE, and right lever for monkeys BE and MA) was illuminated, and 30 responses on the active lever illuminated the lever light red for 2 s, activated the syringe pump, and initiated a 180 s timeout, during which all lights were extinguished. Responses on the active lever during timeouts and on the inactive lever at any time were recorded but had no programmed consequence. A maximum of seven infusions could be obtained per cycle. Multiple unit doses of heroin (0.32-32.0 μg/kg/infusion) were available within a single session, allowing for determination of a heroin dose-effect curve each session (Table 1) . Doses were presented in ascending order, and the unit dose varied across cycles by increasing the infusion duration which ranged from 0.6 to 55 s (0.02-2.1 ml per infusion) across doses and monkeys. Once a suitable range of doses was identified for each monkey, that range was used for a particular monkey for the remainder of the experiment.
Effects of acute Δ
-THC administration
After stable heroin dose-effect curves were established, the effects of Δ 9 -THC were determined first by administering a single dose 3 h prior (McMahon et al., 2005) to the beginning of a heroin self-administration session. A range of doses of Δ 9 -THC was studied, with one determination per dose, and with tests occurring no more frequently than every four sessions, as long as responding was stable during intervening sessions. All monkeys were tested with 0.1 and 0.32 mg/kg of Δ 9 -THC acutely; all monkeys except PE were tested with 0.032 mg/kg of Δ 9 -THC; and MA was tested with 0.01 mg/kg of Δ 9 -THC because in this monkey the larger doses decreased rates substantially (data not shown). After the acute effects of Δ 9 -THC on heroin self-administration were studied, saline was substituted for heroin so that responding delivered an infusion of saline for all cycles of the session (i.e. extinction). Once the total number of infusions obtained per session was half of the average number obtained when heroin was available for three consecutive sessions, the effects of Δ 9 -THC on responding for saline were redetermined.
Effects of daily Δ 9 -THC treatment
After the acute effects of Δ 9 -THC were determined, heroin was again made available for self-administration. In addition, monkeys began receiving twice-daily injections of the Δ 9 -THC vehicle (see below) in the home cage; one injection occurred at 07:00 h (3 h prior to the heroin self-administration session) and the second injection occurred at 19:00 h. The experiment had several phases (Fig. 1) . Initially monkeys responded for heroin while receiving daily Δ 9 -THC vehicle injections (A). After responding for heroin was stable, monkeys received twice-daily injections of a fixed dose of Δ 9 -THC for 14 sessions (B), after which saline was substituted for heroin while monkeys continuing to receive Δ 9 -THC (C). Once either the overall response rate decreased to less than half of the rate maintained when heroin was available, or after seven sessions, heroin was again made available (i.e. resumption; D). After seven additional sessions of heroin self-administration, daily Δ 9 -THC treatment was discontinued (i.e. monkeys received vehicle twice-daily starting with the 07:00 h injection); heroin continued to be available for self-administration (E). After at least seven sessions and a determination that responding for heroin was stable, saline was substituted for heroin (F), followed again by access to heroin and initiation of daily treatment with the next dose of Δ 9 -THC (B). Daily treatment with Δ 9 -THC (0.01, 0.032, and 0.1 mg/kg/12 h) was studied up to a dose that decreased heroin selfadministration when administered acutely (see the Results section); treatment doses were studied in an ascending order for all monkeys.
Data analyses
Response rate was calculated for each cycle by dividing the total number of responses on the active lever by the total time the lever light was illuminated (i.e. total cycle time minus postinjection timeouts). Infusions and response rate were plotted as a function of unit dose of heroin. For extinction and resumption of heroin self-administration, overall rates for the entire session were calculated by taking the average of response rates across the four cycles of a session. Control heroin dose-effect curves represent the mean ( 1 SEM) number of infusions and response rate obtained for the three consecutive sessions immediately prior to the first tests with acute Δ 9 -THC treatment. Control data for sessions during which responding produced saline comprise the mean of response rates across cycles, averaged across each of the three saline substitution sessions prior to the first test with Δ 9 -THC. Heroin was dissolved in 0.9% saline and was administered intravenously contingent upon responding during self-administration sessions. Δ 9 -THC was dissolved in a vehicle comprising a 1 : 1 : 18 mixture of absolute ethanol, Emulphor-620 (Rhone-Poulenc Inc., Princeton, New Jersey, USA), and 0.9% saline and was administered subcutaneously in the back in a volume of 0.2-0.8 ml. At the end of every session, catheters were flushed and locked with 2.5 ml of heparinized saline (100 units/ml; Hospira Inc., Lake Forest, Illinois, USA). Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved.
Statistical analysis
Data were analyzed using repeated-measures withinsubjects analysis of variance (ANOVA). A separate analysis was conducted for each treatment dose of Δ 9 -THC. Post-hoc analyses were conducted using Dunnett's test (Li et al., 2012; Maguire et al., 2013b) . Statistical analyses were conducted using NCSS 8 (NCSS 8 Statistical Software, Kaysville, Utah, USA).
Results
Under baseline conditions, responding for heroin increased and then decreased as a function of unit dose, resulting in an inverted U-shaped dose-effect curve (circles, Fig. 2) , with maximum infusions and response rates occurring during the third cycle of the session, at a unit dose of 3.2 μg/kg/infusion of heroin for PE and MA and 10.0 μg/kg/infusion for NA and BE (Table 1) . In some monkeys administration of the smallest dose of Δ 9 -THC modestly increased rates maintained by smaller unit doses of heroin, whereas larger doses of Δ 9 -THC decreased rates across all unit doses of heroin in all monkeys, resulting in a flattening of the dose-effect curve. Up to the largest dose tested acutely, Δ 9 -THC did not significantly impact the heroin dose-effect curve in PE (data not shown). When saline was substituted for heroin (i.e. extinction), overall response rates (i.e. averaged across all four cycles of the session) decreased by as much as 75% as compared to when heroin was available, with average rates across monkeys ranging from 0.02 to 0.74 responses per second (Table 2 ). Up to a dose of 0.32 mg/kg, pretreatment with Δ 9 -THC did not impact responding for saline in two monkeys (BE and MA), further reduced responding in one monkey (NA), and increased responding in a fourth monkey (PE; Table 2 ).
Heroin dose-effect curves from different time points during chronic treatment were compared to identify any changes in the reinforcing effects of heroin during daily Δ 9 -THC treatment (Fig. 3) . Daily Δ 9 -THC treatment did not significantly increase heroin self-administration at any time in the study, and in some cases modestly decreased responding (e.g. 0.032 mg/kg). For each treatment dose of Δ 9 -THC, ANOVA revealed a significant main effect of heroin dose, but no main effect of time and no interaction.
The left panels of Fig. 4 show infusions (upper panel) and overall response rate (lower panel) averaged for three sessions prior to (data points above 'H') and for up to four sessions during extinction (i.e. substitution of saline for heroin). Daily Δ 9 -THC treatment did not systematically impact extinction of responding in monkeys that had self-administered heroin.
The right panels Fig. 4 show the effect of Δ 9 -THC treatment on resumption of heroin self-administration after extinction (i.e. when heroin was substituted for saline). Infusions and overall response rates are plotted for the last three sessions when saline was available for self-administration (data points above 'S') and for up to four subsequent sessions when heroin was available. Control data (circles) were collected immediately prior to beginning treatment with the smallest dose of Δ 9 -THC; saline maintained low rates of responding that increased markedly when heroin was made available. Daily Δ 9 -THC treatment did not systematically impact resumption of responding for heroin.
Discontinuation of Δ 9 -THC treatment did not impact self-administration of heroin (Fig. 5) . For up to four sessions subsequent to discontinuation of Δ 9 -THC treatment, infusions of and response rates for heroin were comparable to those during treatment.
Discussion
Recent increases in abuse of heroin and of prescription opioids [e.g. Office of National Drug Control Policy (ONDCP), 2011; Substance Abuse and Mental Health Services Administration (SAMHSA), 2013] represent a significant and growing public health problem resulting in significant economic and human costs (e.g. Hansen et al., 2011) . Moreover, recent reports indicating an increase in the coingestion of opioids with other drugs such as marijuana (e.g. McCabe et al., 2012) is particularly problematic since polydrug abuse increases the risk of encountering adverse health consequences and reduces treatment effectiveness (e.g. Cone et al., 2004; Williamson et al., 2006) . The current study examined the impact of daily Δ 9 -THC treatment on different aspects of heroin self-administration in rhesus monkeys in order to determine whether repeated treatment or discontinuation of treatment with a cannabinoid receptor agonist alters the positive reinforcing effects of a mu opioid receptor agonist.
Consistent with previous studies (e.g. Gerak et al., 2009; Maguire et al., 2013a) , heroin maintained selfadministration across a range of doses which varied across cycles during the session. In some cases, small doses of Δ 9 -THC increased response rates maintained by smaller doses of heroin (NA and BE), possibly indicating an increase in the positive reinforcing effects of heroin; however, those effects were small and inconsistent across monkeys. Pretreatment with larger doses of Δ 9 -THC markedly decreased responding and flattened the heroin dose-effect curve. At doses in the range of those producing significant behavioral and hormonal effects in humans (D'Souza et al., 2004) , twice-daily treatment with Δ 9 -THC (up to a dose of 0.1 mg/kg) failed to significantly increase lever-pressing maintained by intravenous injections of heroin, indicating that repeated treatment with a cannabinoid receptor agonist likely does not enhance the positive reinforcing effects of a mu opioid receptor agonist. These data are consistent with previous work showing that acute administration of a cannabinoid receptor agonist fails to enhance heroin selfadministration in rhesus monkeys, when one (Li et al., 2012) or multiple (Maguire et al., 2013a) doses of heroin were available for self-administration per session, and extend this work to indicate that repeated administration of a cannabinoid receptor agonist does not substantially increase self-administration of a mu opioid receptor agonist. Similarly, daily treatment with Δ 9 -THC also failed to alter the extinction of heroin self-administration upon substitution of saline for heroin, or the resumption of responding when heroin was again made available.
Cannabinoid receptor agonists and mu opioid receptor agonists share many pharmacological effects (e.g. Vigano et al., 2005; Bushlin et al., 2010; Scavone et al., 2013) , including modulation of dopamine neurotransmission (e.g. Tanda and Goldberg, 2003) . Therefore, it might be expected that cannabinoids would alter the reinforcing effects of opioids and that opioids would alter the -THC on heroin self-administration. Δ 9 -THC was administered subcutaneously 3 h prior to the start of the session and heroin was delivered intravenously according to a fixed-ratio 30 schedule of reinforcement. The dose of heroin available for selfadministration increased across cycles within session (see Table 1 for doses of heroin available in each cycle for individual monkeys). Included are data from three sessions immediately prior to the first test with Δ 9 -THC (circles) and following treatment with different doses of Δ 9 -THC (triangles, diamonds, and squares). The filled symbol indicates that the effect obtained was significantly different from heroin alone. Monkey PE was not tested with 0.032 mg/kg of Δ 9 -THC. Horizontal axis: cycle. Vertical axis: mean infusions (upper panel) or response rate (lower panel) 1 SEM. ANOVA revealed a significant main effect of dose of Δ 9 -THC on infusions [F(3,56) = 11.8, P < 0.001] and response rate [F(3,56) = 3.8, P < 0.02]. ANOVA, analysis of variance; Δ 9 -THC, delta-9-tetrahydrocannabinol. reinforcing effects of cannabinoids. Indeed, some preclinical research shows that cannabinoid receptor agonists such as Δ 9 -THC enhance some effects (e.g. discriminative stimulus and positive reinforcing effects) of mu opioid receptor agonists (e.g. Norwood et al., 2003; Solinas et al., 2005 ; see also De Vries et al., 2003; Fattore et al., 2003) . Moreover, repeated administration of a cannabinoid receptor agonist can enhance some effects of a mu opioid receptor agonist (and vice versa) in rats (e.g. Cadoni et al., 2001) . However, interactions between the behavioral effects of cannabinoids and opioids appear to depend upon several factors including the species as well as the experimental conditions under which they are studied. For example, heroin and morphine enhance the discriminative stimulus effects of Δ 9 -THC in rats (Solinas et al., 2005) but not in rhesus monkeys (Li et al., 2008) . Δ 9 -THC attenuates the discriminative stimulus effects of morphine in nondependent rhesus monkeys while having no effect on the discriminative stimulus effects of morphine in morphine-treated (i.e. opioid-dependent) monkeys (Li et al., 2008) . Clearly more research is required to understand the interaction between these commonly abused classes of drugs.
Discontinuation of repeated treatment with a drug can also impact behavior, possibly reflecting withdrawal resulting from the development of physical dependence. Although dependence on cannabinoid receptor agonists has typically been more difficult to demonstrate in animal models, compared with dependence on other drugs such as opioids [e.g. see review by Maldonado (2002) ], some evidence suggests that discontinuation of chronic Δ 9 -THC treatment can impact operant behavior. For example, in rhesus monkeys, discontinuation of a continuous intravenous infusion of Δ 9 -THC (0.05 mg/kg/h) decreased rates of food-maintained operant responding in rhesus monkeys (Beardsley et al., 1986) , an effect that Fig. 1; circles) , the first three sessions of treatment (beginning of phase B in Fig. 1; triangles) , the last three sessions of treatment (end of phase D in Fig. 1; diamonds) . emerged on the second day following discontinuation and lasted for up to a week. One possibility is that discontinuation of treatment with one drug (e.g. opioid) increases responding for other drugs having different mechanisms of action (e.g. cocaine; Gerak et al., 2009) . Therefore, it might be the case that discontinuation of treatment with Δ 9 -THC increases heroin selfadministration. However, in the current study, discontinuation of treatment with Δ 9 -THC did not substantially impact rates of heroin self-administration for up to 1 week following discontinuation. These data suggest that discontinuation of treatment with a cannabinoid receptor agonist likely does not impact the positive reinforcing effects of mu opioid receptor agonists. It is possible that treatment with larger doses of Δ 9 -THC or for longer periods modifies various aspects of heroin selfadministration. However, other studies have shown that tolerance to the behavioral effects of Δ 9 -THC emerges within the first few weeks, or even days, of treatment (Harris et al., 1972; Fredericks and Benowitz, 1980; Beardsley et al., 1986; McMahon, 2011; Hruba et al., 2012) . Moreover, effects of discontinuation of treatment in some cases are evident after as few as 10 days of treatment and following treatment with doses that produce no observable effects on behavior during treatment (Beardsley et al., 1986) . It is possible that treatment with 
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-THC treatment on extinction of heroin self-administration (phase C in Fig. 1 ). The average number of infusions (upper panel) and overall response rate (lower panel) for last three sessions of heroin self-administration are plotted above 'H', as are the overall responses rates for each of the first four sessions following substitution of saline for heroin (see Data Analyses for further details). Right panels: effects of twice-daily Δ 9 -THC treatment on resumption of heroin self-administration (phase D in Fig. 1 ). The average number of infusions (upper panel) and overall response rate (lower panel) for the last three sessions of extinction, during which saline was substituted for heroin, is plotted above 'S' , as are the overall response rates for each of the first four sessions following substitution of heroin for saline. Session is indicated on the horizontal axis and total infusions (upper panels) or overall response rate (lower panels) 1 SEM is indicated on the vertical axis. ANOVA revealed a significant main effect of session on infusions [F(4,74) = 18.4, P < 0.001] and response rate [F(4,74) = 5.2, P < 0.001] for extinction, and a significant main effect of session on infusions [F(4,74) = 13.3, P < 0.001] and response rate [F(4,74) = 4.5, P < 0.005] for resumption of heroin self-administration. ANOVA, analysis of variance; Δ larger doses of Δ 9 -THC or treatment with cannabinoid receptor agonists that are metabolized and eliminated more quickly, such as WIN 55,212, might result in a more substantial effect upon discontinuation of treatment (e.g. Aceto et al., 2001) .
In summary, this study examined the effects of daily Δ 9 -THC treatment on heroin self-administration in rhesus monkeys. When administered acutely, Δ 9 -THC dose dependently decreased heroin self-administration in most subjects. Twice-daily treatment with Δ 9 -THC failed to enhance, and in some cases attenuated, heroin self-administration, but otherwise had no significant effect. Furthermore, discontinuation of daily treatment did not impact heroin self-administration. These data suggest that coadministration of a cannabinoid receptor agonist and an opioid receptor agonist likely does not enhance the positive reinforcing effects of the opioid.
